

Disposition of Participants

| | Placebo | | Xanomeline Low Dose | | Xanomeline High Dose | |
|----------------------------|---------|------|---------------------|------|----------------------|------|
| | n | (%) | n | (%) | n | (%) |
| Participants in population | 86 | | 84 | | 84 | |
| Completed | 58 | 67.4 | 25 | 29.8 | 27 | 32.1 |
| Discontinued | 28 | 32.6 | 59 | 70.2 | 57 | 67.9 |
| Adverse Event | 8 | 9.3 | 44 | 52.4 | 40 | 47.6 |
| Death | 2 | 2.3 | 1 | 1.2 | 0 | 0.0 |
| I/E Not Met | 1 | 1.2 | 0 | 0.0 | 2 | 2.4 |
| Lack of Efficacy | 3 | 3.5 | 0 | 0.0 | 1 | 1.2 |
| Lost to Follow-up | 1 | 1.2 | 1 | 1.2 | 0 | 0.0 |
| Physician Decision | 1 | 1.2 | 0 | 0.0 | 2 | 2.4 |
| Protocol Violation | 1 | 1.2 | 1 | 1.2 | 1 | 1.2 |
| Sponsor Decision | 2 | 2.3 | 2 | 2.4 | 3 | 3.6 |
| Withdrew Consent | 9 | 10.5 | 10 | 11.9 | 8 | 9.5 |

Source: ADSL dataset